Lilly and the FDA head for a decision on whether retatrutide counts as a biologic

Eli Lilly is preparing to file its obesity drug retatrutide for U.S. approval in the first quarter of 2027, but an unresolved legal dispute with the Food and Drug Administration over how to classify the drug could affect that timeline and, more importantly, how long other companies are kept out of the market ^[1].

At issue is whether retatrutide counts as a biologic or a standard drug. Lilly says the medicine has 41 amino acids, which under FDA rules should qualify it as a protein and therefore a biologic, since the agency's definition covers any amino acid polymer with 40 or more amino acids ^[1]. The FDA disagrees. The agency says that while retatrutide is an amino acid polymer, it does not have 40 or more "alpha amino acids," a narrower category the agency says is the correct standard, and it has classified the drug as a standard drug instead ^[1].

The distinction is not just technical. A biologics license application, or BLA, would give Lilly 12 years of market exclusivity. A new drug application, or NDA, would give the company only five years ^[1]. Lilly sued the FDA over the classification in September 2024 ^[1]. Oral arguments took place in September 2025, and a court has since vacated the FDA's decision but sent the separate question of whether retatrutide is "analogous to" a protein back to the agency ^[1]. Lilly has appealed that ruling ^[1].

Lilly CEO Dave Ricks addressed the dispute on the company's second-quarter earnings call, saying "we believe retatrutide is a biologic application, both in terms of amino acid count rule as well as analogous to a protein, so that's our position" ^[1]. Ricks said the company hopes to resolve the matter with the FDA in time to support a BLA filing, adding, "Obviously, it's active litigation, but we would hope to come to a conclusion with the FDA to support a BLA application" ^[1]. He also said that if the FDA rejects a BLA, the drug's approval could be delayed ^[1].

Lilly has said it has the data it needs to file for approval of retatrutide for obesity, obstructive sleep apnea, and knee osteoarthritis pain, and is still gathering manufacturing-related data ahead of the planned first-quarter 2027 submission ^[1]. Retatrutide is a triple-hormone drug, sometimes called a "triple-G" therapy, and in Phase 3 trials called TRIUMPH-2 and TRIUMPH-3 it showed weight loss topping 20% at 80 weeks ^[1].

Why it matters for patients

This dispute will not change whether retatrutide works, but it could shape how much it costs and for how long. A 12-year exclusivity period under a BLA would keep any generic or biosimilar version of retatrutide off the market far longer than the five years an NDA classification would allow ^[1]. For patients who already pay high out-of-pocket costs for GLP-1 and related drugs, that difference could mean waiting years longer for lower-cost alternatives to reach pharmacy shelves.

The case could also set a precedent for other incretin drugs still in development. Lilly noted that future medicines in this class could face the same kind of classification fight over a small difference in amino acid count ^[1]. That means the outcome here may affect exclusivity timelines, and eventually pricing and access, for drugs beyond retatrutide itself.

For now, retatrutide is not yet approved anywhere, and the classification question remains unresolved in court. It is not yet known how the FDA or the courts will ultimately rule, or whether the dispute will delay Lilly's planned submission.

What happens next

An appeals court has set a hearing for September 2026 [headline]. Lilly has said it is targeting a first-quarter 2027 regulatory filing for retatrutide covering obesity, obstructive sleep apnea, and knee osteoarthritis pain, and has said it will update investors as the classification dispute with the FDA progresses ^[1].